Genincode

Genincode Diluted EPS

The Diluted Earnings per Share of Genincode (GENI.L) as of Oct 27, 2026 is -0.02 GBP. In the previous year, Diluted Earnings per Share was -0.03 GBP — a change of -20.28% (higher).

Diluted EPS

-0.02GBP

YoY

-20.28%

Last updated:

Diluted Earnings per Share of Genincode is 2025 -0.02 GBP. Diluted Earnings per Share of Genincode was 2024 -0.03 GBP. It decreases by -20.28% higher compared to the previous year.

The Genincode Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2019
-6.03 GBP
Jan 1, 2020
-0.10 GBP
Jan 1, 2021
-0.04 GBP
Jan 1, 2022
-0.06 GBP
Jan 1, 2023
-0.07 GBP
Jan 1, 2024
-0.03 GBP
Jan 1, 2025
-0.02 GBP
The Genincode Diluted EPS history
YEARDiluted EPSYoY
-0.02GBP-20.28%
-0.03GBP-65.78%
-0.07GBP+26.21%
-0.06GBP+34.21%
-0.04GBP-58.32%
-0.10GBP-98.28%
-6.03GBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genincode Stock analysis

What does Genincode do? GENinCode Plc generates revenue through its genetic risk assessment products for cardiovascular disease, including Cardio Incode, Lipid Incode, Sudd Incode, Roca Test, Thrombo, and Thrombo Incode Reproductive Health. The company targets healthcare practitioners who use its genomic precision testing, combining polygenic technology, molecular testing, genotyping, sequencing, and AI bioinformatics to assess patient DNA risk. Its products integrate genetic and clinical data to provide predictive care strategies for cardiovascular disease prevention. The firm serves medical professionals seeking advanced tools for patient risk evaluation and treatment planning. The company's wholly owned subsidiaries, GENinCode S.L.U. and GENinCode U.S. INC., support its global operations in risk assessment and prevention services. GENinCode Plc's focus on cardiovascular disease risk assessment leverages AI-driven bioinformatics to deliver tailored preventative care solutions. Healthcare providers utilize its comprehensive testing suite to enhance clinical decision-making and patient outcomes in cardiovascular health management. Genincode is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genincode stock

Diluted Earnings per Share of Genincode is -0.02 GBP in 2025.

Diluted Earnings per Share of Genincode changed from -0.03 GBP to -0.02 GBP, representing a -20.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Genincode since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Genincode

All Key Metrics — Genincode